AP2014008013A0 - Methods of producing anamorelin hydrochloride having controlled chloride content - Google Patents

Methods of producing anamorelin hydrochloride having controlled chloride content

Info

Publication number
AP2014008013A0
AP2014008013A0 AP2014008013A AP2014008013A AP2014008013A0 AP 2014008013 A0 AP2014008013 A0 AP 2014008013A0 AP 2014008013 A AP2014008013 A AP 2014008013A AP 2014008013 A AP2014008013 A AP 2014008013A AP 2014008013 A0 AP2014008013 A0 AP 2014008013A0
Authority
AP
ARIPO
Prior art keywords
methods
chloride content
controlled chloride
anamorelin hydrochloride
producing
Prior art date
Application number
AP2014008013A
Other languages
English (en)
Inventor
Seemon Pines
Rubio Silvina Garcia
Peter Manini
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48225135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2014008013(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of AP2014008013A0 publication Critical patent/AP2014008013A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AP2014008013A 2012-04-20 2013-04-18 Methods of producing anamorelin hydrochloride having controlled chloride content AP2014008013A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261636108P 2012-04-20 2012-04-20
PCT/US2013/037159 WO2013158874A1 (en) 2012-04-20 2013-04-18 Methods of producing anamorelin hydrochloride having controlled chloride content

Publications (1)

Publication Number Publication Date
AP2014008013A0 true AP2014008013A0 (en) 2014-10-31

Family

ID=48225135

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2014008013A AP2014008013A0 (en) 2012-04-20 2013-04-18 Methods of producing anamorelin hydrochloride having controlled chloride content

Country Status (47)

Country Link
US (8) US20140018391A1 (da)
EP (3) EP3290410B1 (da)
JP (3) JP6109925B2 (da)
KR (2) KR101972998B1 (da)
CN (3) CN110041304A (da)
AP (1) AP2014008013A0 (da)
AR (1) AR090725A1 (da)
AU (1) AU2013249197B2 (da)
BR (1) BR112014025972A8 (da)
CA (2) CA3031652C (da)
CL (1) CL2014002817A1 (da)
CO (1) CO7131356A2 (da)
CR (1) CR20140530A (da)
CY (1) CY1120276T1 (da)
DK (2) DK2838892T3 (da)
DO (1) DOP2014000235A (da)
EA (1) EA031581B1 (da)
EC (1) ECSP14027739A (da)
ES (2) ES2658862T3 (da)
GE (1) GEP20186902B (da)
HK (2) HK1202863A1 (da)
HR (1) HRP20180316T1 (da)
HU (2) HUE035697T2 (da)
IL (1) IL235064B (da)
JO (1) JO3353B1 (da)
LT (1) LT2838892T (da)
MA (1) MA37524B1 (da)
MD (1) MD4615C1 (da)
ME (1) ME02966B (da)
MX (1) MX354793B (da)
MY (1) MY170068A (da)
NI (1) NI201400124A (da)
NO (1) NO2877697T3 (da)
NZ (1) NZ700833A (da)
PE (1) PE20150084A1 (da)
PH (1) PH12014502351B1 (da)
PL (2) PL3290410T3 (da)
PT (2) PT2838892T (da)
RS (1) RS56869B1 (da)
SG (2) SG11201406478XA (da)
SI (2) SI2838892T1 (da)
TN (1) TN2014000421A1 (da)
TW (2) TWI589572B (da)
UA (1) UA116207C2 (da)
UY (1) UY34753A (da)
WO (1) WO2013158874A1 (da)
ZA (1) ZA201408508B (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3353B1 (ar) 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
CN113577074A (zh) * 2014-09-04 2021-11-02 赫尔森保健股份公司 基于阿拉莫林的药物治疗
KR20180086300A (ko) 2015-07-24 2018-07-30 뉴링크 제네틱스 코퍼레이션 1-메틸-d-트립토판의 염 및 프로드러그
CN108239141A (zh) * 2016-12-23 2018-07-03 江苏先声药业有限公司 一种阿拉莫林的制备方法
KR20220054244A (ko) 2019-08-30 2022-05-02 헬신 헬스케어 에스아 개선된 안정성을 갖는 아나모렐린 정제의 제조 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73530C2 (uk) * 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
CN1882526A (zh) * 2003-09-26 2006-12-20 兰贝克赛实验室有限公司 制备伏格列波糖的方法
EP2298760B1 (en) 2004-06-29 2015-08-05 Helsinn Healthcare S.A. Crystal forms of (3R)-1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
MX2009008561A (es) * 2007-02-13 2010-01-15 Helsinn Therapeutics Us Inc Metodo para tratar trastornos proliferativos celulares utilizando secretagogos.
UA105657C2 (uk) * 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Поліпшені способи лікування мігрені на основі анамореліну
JO3353B1 (ar) 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي

Also Published As

Publication number Publication date
US9981002B2 (en) 2018-05-29
UY34753A (es) 2013-11-29
WO2013158874A1 (en) 2013-10-24
CR20140530A (es) 2015-03-25
US20190231843A1 (en) 2019-08-01
SG11201406478XA (en) 2014-11-27
JP6616853B2 (ja) 2019-12-04
EP2838892B1 (en) 2017-12-06
AU2013249197B2 (en) 2017-04-06
US20160229889A1 (en) 2016-08-11
KR101972998B1 (ko) 2019-04-29
AU2013249197A1 (en) 2014-10-30
MX2014012178A (es) 2015-08-05
SI3290410T1 (sl) 2020-11-30
NI201400124A (es) 2015-09-21
TWI589572B (zh) 2017-07-01
JO3353B1 (ar) 2019-03-13
HK1202863A1 (en) 2015-10-09
CA2869893C (en) 2019-03-05
BR112014025972A8 (pt) 2021-06-22
US10905737B2 (en) 2021-02-02
CN110041304A (zh) 2019-07-23
LT2838892T (lt) 2018-03-12
CY1120276T1 (el) 2019-07-10
EA201401151A1 (ru) 2015-06-30
GEP20186902B (en) 2018-10-25
JP2018076375A (ja) 2018-05-17
MA37524A1 (fr) 2016-06-30
KR20150013115A (ko) 2015-02-04
CN103857669A (zh) 2014-06-11
PT2838892T (pt) 2018-02-28
DK3517532T3 (da) 2022-01-03
MD4615B1 (ro) 2019-01-31
ZA201408508B (en) 2020-01-29
PH12014502351A1 (en) 2015-01-12
JP6109925B2 (ja) 2017-04-05
ME02966B (me) 2018-07-20
SI2838892T1 (en) 2018-05-31
IL235064A0 (en) 2014-12-31
ECSP14027739A (es) 2015-12-31
US20140018391A1 (en) 2014-01-16
US20160235804A1 (en) 2016-08-18
EP2838892A1 (en) 2015-02-25
JP2015514779A (ja) 2015-05-21
US10300105B2 (en) 2019-05-28
KR102141323B1 (ko) 2020-08-05
MA37524B1 (fr) 2017-04-28
EA031581B1 (ru) 2019-01-31
TWI677494B (zh) 2019-11-21
ES2658862T3 (es) 2018-03-12
MY170068A (en) 2019-07-03
UA116207C2 (uk) 2018-02-26
BR112014025972A2 (pt) 2017-06-27
EP3517532A1 (en) 2019-07-31
MX354793B (es) 2018-03-21
CN103857669B (zh) 2019-06-28
CN110041398A (zh) 2019-07-23
US9956261B2 (en) 2018-05-01
HK1248694A1 (zh) 2018-10-19
PL2838892T3 (pl) 2018-05-30
HUE050865T2 (hu) 2021-01-28
US9872883B2 (en) 2018-01-23
JP6284665B2 (ja) 2018-02-28
HRP20180316T1 (hr) 2018-04-06
PT3517532T (pt) 2021-11-08
DK2838892T3 (da) 2018-03-12
CA2869893A1 (en) 2013-10-24
MD20140122A2 (ro) 2015-05-31
TW201348224A (zh) 2013-12-01
US9403867B2 (en) 2016-08-02
US20190000914A1 (en) 2019-01-03
US20150072934A1 (en) 2015-03-12
EP3290410A1 (en) 2018-03-07
SG10201608488RA (en) 2016-12-29
RS56869B1 (sr) 2018-04-30
MD4615C1 (ro) 2019-08-31
PH12014502351B1 (en) 2015-01-12
EP3517532B1 (en) 2021-10-13
CO7131356A2 (es) 2014-12-01
NZ700833A (en) 2016-01-29
DOP2014000235A (es) 2015-01-31
US20200276259A1 (en) 2020-09-03
CL2014002817A1 (es) 2015-08-14
TW201722928A (zh) 2017-07-01
CA3031652A1 (en) 2013-10-24
KR20190044697A (ko) 2019-04-30
TN2014000421A1 (en) 2016-03-30
HUE035697T2 (en) 2018-05-28
US20160237115A1 (en) 2016-08-18
JP2017101082A (ja) 2017-06-08
IL235064B (en) 2019-09-26
PL3290410T3 (pl) 2021-01-11
US10576122B2 (en) 2020-03-03
CA3031652C (en) 2020-10-27
AR090725A1 (es) 2014-12-03
ES2820354T3 (es) 2021-04-20
PE20150084A1 (es) 2015-01-23
EP3290410B1 (en) 2020-07-01
NO2877697T3 (da) 2018-10-13

Similar Documents

Publication Publication Date Title
HUE037048T2 (hu) Eljárások 4-cikloalkiloxibenzolszulfonamidok elõállítására
HK1219414A1 (zh) 治療關節炎的方法
EP2717855A4 (en) PROCESSING METHODS
HK1248694A1 (zh) 製備具有受控氯化物含量的阿拉莫林鹽酸鹽的方法
ZA201406494B (en) Methods of producing sulfilimine compounds
EP2800476A4 (en) FEEDING METHOD
HK1209790A1 (en) Method of producing recombinant iduronate-2-sulfatase -2-
PL2836460T3 (pl) Sposób wytwarzania grafenu
PL2931937T3 (pl) Sposób wytwarzania układów nanocząstek metali
IL237862A0 (en) Methods to reduce the formation of scale
GB201220155D0 (en) Method of manufacture
GB201215942D0 (en) Method of treatent
EP2887938A4 (en) PROCESS FOR PREPARING TECOVIRIMAT
ZA201503833B (en) Method of hemoglobin-f determination
GB201221118D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment
GB201206326D0 (en) Methods of treatment
GB201206330D0 (en) Methods of treatment
GB201206325D0 (en) Methods of treatment
GB201206324D0 (en) Methods of treatment
GB201221032D0 (en) Method of treatment
GB201212279D0 (en) Method of construction
GB201207894D0 (en) Method of treatment
GB201203868D0 (en) Method of feeding